DekaBank Deutsche Girozentrale maintained its stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 69,800 shares of the biopharmaceutical company’s stock at the end of the second quarter. DekaBank Deutsche Girozentrale owned approximately 0.05% of Achillion Pharmaceuticals worth $314,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. TradeLink Capital LLC acquired a new stake in Achillion Pharmaceuticals during the second quarter valued at approximately $132,000. Teza Capital Management LLC acquired a new stake in Achillion Pharmaceuticals during the first quarter valued at approximately $131,000. Dynamic Technology Lab Private Ltd acquired a new stake in Achillion Pharmaceuticals during the first quarter valued at approximately $138,000. Highbridge Capital Management LLC acquired a new stake in Achillion Pharmaceuticals during the first quarter valued at approximately $149,000. Finally, Canada Pension Plan Investment Board increased its stake in Achillion Pharmaceuticals by 4.7% in the first quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,600 shares in the last quarter. 74.12% of the stock is owned by institutional investors.

Shares of Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) opened at 4.98 on Wednesday. The company’s 50 day moving average is $4.46 and its 200 day moving average is $4.18. The company’s market capitalization is $681.07 million. Achillion Pharmaceuticals, Inc. has a 12-month low of $3.15 and a 12-month high of $9.19.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). During the same period in the previous year, the business earned ($0.14) EPS. Analysts expect that Achillion Pharmaceuticals, Inc. will post ($0.63) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “DekaBank Deutsche Girozentrale Continues to Hold Position in Achillion Pharmaceuticals, Inc. (ACHN)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/dekabank-deutsche-girozentrale-continues-to-hold-position-in-achillion-pharmaceuticals-inc-achn/1530911.html.

Several analysts have commented on the stock. Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Robert W. Baird downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 target price for the company. in a research report on Thursday, August 10th. Maxim Group set a $7.00 target price on shares of Achillion Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. BidaskClub raised shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 16th. Finally, Chardan Capital decreased their target price on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $8.25.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.